跳至主要内容
临床试验/NCT05483257
NCT05483257已完成不适用

Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study

BAIYONG SHEN1 个研究点 分布在 1 个国家目标入组 226 人开始时间: 2018年3月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
226
试验地点
1
主要终点
Disease-free survival (DFS)

研究概览

简要总结

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
34 Years 至 84 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Radically resected pancreatic adenocarcinoma (stage I-III)
  • Resected tumor tissues and matched blood cells available
  • Signed informed consent

排除标准

  • Pancreatic cancer except pancreatic adenocarcinoma
  • Non-radical resection

结局指标

主要结局

Disease-free survival (DFS)

时间窗: 2 years

Comparison of DFS between patients with specific HLA-I genotypes or not

次要结局

未报告次要终点

研究者

发起方
BAIYONG SHEN
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

BAIYONG SHEN

Professor

Ruijin Hospital

研究点 (1)

Loading locations...

相似试验